معرفی
Francis P. Worden serves as Clinical Professor of Internal Medicine at the University of Michigan Medical School, holding the Nancy Wigginton Oncology Research Professorship of Thyroid Cancer. He is an active member of the Rogel Cancer Center and available for academic mentorship, with current research engagement evidenced by multiple 2024-2025 publications.
Dr. Worden's research centers on thyroid cancer and head/neck malignancies, specializing in molecular characterization of tumors, targeted therapies, and immunotherapeutic approaches. His work bridges laboratory findings to clinical applications through national guideline development (NCCN Thyroid Carcinoma) and innovative clinical trials evaluating agents like selpercatinib, pembrolizumab, and lenvatinib for advanced disease.
Recent publications reveal a strong focus on precision oncology, with significant contributions to RET-activated thyroid cancer treatment durability, HPV-related oropharynx cancer management, and radioiodine-refractory differentiated thyroid cancer therapies. His research integrates patient-reported outcomes and molecular profiling to address therapeutic resistance and survivorship challenges.
As a Rogel Cancer Center member, Dr. Worden collaborates within multidisciplinary teams advancing translational cancer research. His leadership in clinical trials and national guidelines demonstrates commitment to improving outcomes for patients with complex endocrine and head/neck cancers through evidence-based therapeutic innovations.
